NASDAQ:COEP Coeptis Therapeutics (COEP) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free COEP Stock Alerts $0.36 -0.01 (-2.70%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.36▼$0.4150-Day Range$0.30▼$0.5852-Week Range$0.29▼$2.19Volume316,087 shsAverage Volume246,799 shsMarket Capitalization$12.99 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Coeptis Therapeutics alerts: Email Address Coeptis Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside733.3% Upside$3.00 Price TargetShort InterestHealthy0.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.92 out of 5 starsMedical Sector3895th out of 5,424 stocksBiological Products, Except Diagnostic Industry622nd out of 909 stocks 3.5 Analyst's Opinion Consensus RatingCoeptis Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCoeptis Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.66% of the float of Coeptis Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoeptis Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coeptis Therapeutics has recently increased by 61.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCoeptis Therapeutics does not currently pay a dividend.Dividend GrowthCoeptis Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COEP. Previous Next 2.3 News and Social Media Coverage News SentimentCoeptis Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Coeptis Therapeutics this week, compared to 0 articles on an average week.Search Interest4 people have searched for COEP on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Coeptis Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coeptis Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.49% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.88% of the stock of Coeptis Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Coeptis Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coeptis Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoeptis Therapeutics has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Coeptis Therapeutics Stock (NASDAQ:COEP)Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.Read More COEP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COEP Stock News HeadlinesMay 3, 2024 | americanbankingnews.comZura Bio (NASDAQ:ZURA) & Coeptis Therapeutics (NASDAQ:COEP) Head to Head SurveyMay 2, 2024 | prnewswire.comCoeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingMay 4, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 29, 2024 | americanbankingnews.comCoeptis Therapeutics (NASDAQ:COEP) versus Neumora Therapeutics (NASDAQ:NMRA) Financial ComparisonApril 29, 2024 | americanbankingnews.comCoeptis Therapeutics (COEP) and The Competition Head-To-Head AnalysisApril 27, 2024 | americanbankingnews.comCoeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest UpdateApril 25, 2024 | americanbankingnews.comFinancial Contrast: Coeptis Therapeutics (COEP) and Its RivalsApril 24, 2024 | finance.yahoo.comDeverra Therapeutics Granted FDA Fast Track Designation for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid LeukemiaMay 4, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 2, 2024 | prnewswire.comCoeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research AwardApril 1, 2024 | investorplace.comCOEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023February 28, 2024 | investing.comCoeptis expands license for CAR technology to autoimmune diseasesFebruary 26, 2024 | finance.yahoo.comCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKFebruary 26, 2024 | prnewswire.comCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKFebruary 17, 2024 | morningstar.comCoeptis Therapeutics Holdings Inc Ordinary Shares COEPFebruary 7, 2024 | finance.yahoo.comCoeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral InfectionsFebruary 2, 2024 | msn.comCoeptis Therapeutics Risks Nasdaq Delisting Over Bid PriceJanuary 4, 2024 | finance.yahoo.comCoeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024December 9, 2023 | benzinga.comCoeptis Therapeutics Stock (NASDAQ:COEP) Insider TradesDecember 4, 2023 | finance.yahoo.comCoeptis Therapeutics to Present at the Emerging Growth ConferenceNovember 15, 2023 | markets.businessinsider.comBuy Rating for Coeptis Therapeutics Holdings Amidst Promising Cancer Cell Therapy Platforms and Exclusive Licensing AssetsOctober 31, 2023 | finance.yahoo.comCoeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023October 24, 2023 | msn.comCoeptis Therapeutics to raise $2M in a private placementOctober 24, 2023 | finance.yahoo.comCoeptis Therapeutics Announces $2 Million Private PlacementOctober 11, 2023 | bizjournals.comLocal pharma firm widens technology deal with the University of PittsburghOctober 11, 2023 | markets.businessinsider.comCoeptis Expands License Agreement With University Of Pittsburgh To Include SNAP-CAR PlatformOctober 9, 2023 | finance.yahoo.comCoeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesSee More Headlines Receive COEP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/04/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:COEP CUSIPN/A CIK1759186 Webcoeptispharma.com Phone724-934-6467FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+733.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-794.75% Return on Assets-322.86% Debt Debt-to-Equity Ratio0.03 Current Ratio1.76 Quick Ratio1.76 Sales & Book Value Annual Sales$80,000.00 Price / Sales162.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book2.77Miscellaneous Outstanding Shares36,090,000Free Float28,334,000Market Cap$12.99 million OptionableNot Optionable Beta-0.92 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. David Mehalick (Age 55)Co-Founder, Chairman of the Board, CEO & President Comp: $360kMs. Christine Elise Sheehy (Age 56)Co-Founder and VP of Compliance & Corporate Secretary Comp: $151kMr. Daniel Alexander Yerace (Age 41)Co-Founder, VP of Operations & Director Comp: $360kMr. Brian Cogley M.B.A. (Age 37)Chief Financial Officer Comp: $208kDr. Colleen Delaney M.D. (Age 56)M.Sc., CSO & Chief Medical Officer Comp: $360kKey CompetitorsOrganovoNASDAQ:ONVOChromocell TherapeuticsNYSE:CHROBioCardiaNASDAQ:BCDAInhibikase TherapeuticsNYSE:IKTGenetic TechnologiesNASDAQ:GENEView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 1,308,000 shares on 2/13/2024Ownership: 10.320%Tara DesilvaBought 2,266 shares on 1/12/2024Total: $1,314.28 ($0.58/share)Brian CogleyBought 5,000 shares on 1/10/2024Total: $3,350.00 ($0.67/share)David MehalickBought 20,004 shares on 1/8/2024Total: $13,202.64 ($0.66/share)Daniel Alexander YeraceBought 10,850 shares on 1/5/2024Total: $7,486.50 ($0.69/share)View All Insider TransactionsView All Institutional Transactions COEP Stock Analysis - Frequently Asked Questions Should I buy or sell Coeptis Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coeptis Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" COEP shares. View COEP analyst ratings or view top-rated stocks. What is Coeptis Therapeutics' stock price target for 2024? 1 brokerages have issued twelve-month price targets for Coeptis Therapeutics' shares. Their COEP share price targets range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price. View analysts price targets for COEP or view top-rated stocks among Wall Street analysts. How have COEP shares performed in 2024? Coeptis Therapeutics' stock was trading at $0.7839 at the beginning of 2024. Since then, COEP stock has decreased by 54.1% and is now trading at $0.36. View the best growth stocks for 2024 here. Are investors shorting Coeptis Therapeutics? Coeptis Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 174,300 shares, an increase of 61.8% from the March 31st total of 107,700 shares. Based on an average trading volume of 257,400 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.7% of the company's shares are sold short. View Coeptis Therapeutics' Short Interest. When is Coeptis Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our COEP earnings forecast. How were Coeptis Therapeutics' earnings last quarter? Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) issued its earnings results on Monday, March, 25th. The company reported ($0.08) earnings per share for the quarter. How do I buy shares of Coeptis Therapeutics? Shares of COEP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COEP) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
